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Abstract
Primary erythromelalgia (PE ORPHA90026) is a rare autosomal dominant neuropathy characterized by the
combination of recurrent burning pain, warmth and redness of the extremities. The incidence rate of PE ranges
from 0.36 to 1.1 per 100,000 persons. Gender ratio differs according to different studies and no evidence showed a
gender preference. Clinical onset of PE is often in the first decade of life. Burning pain is the most predominant
symptom and is usually caused and precipitated by warmth and physical activities. Reported cases of PE contain
both inherited and sporadic forms. Genetic etiology of PE is mutations on SCN9A, the encoding gene of a voltage-
gated sodium channel subtype Nav1.7. Diagnosis of PE is made upon clinical manifestations and screening
for mutations on SCN9A. Exclusion of several other treatable diseases/secondary erythromelalgia is also necessary
because of the lack of biomarkers specifically for PE. Differential diagnoses can include Fabry disease, cellulites,
Raynaud phenomenon, vasculitis and so on. Diagnostic methods often involve complete blood count, imaging
studies and thermograph. Treatment for PE is unsatisfactory and highly individualized. Frequently used pain
relieving drugs involve sodium channel blockers such as lidocaine, carbamazepine and mexiletine. Novel drugs
such as PF-05089771 and TV-45070 could be promising in ameliorating pain symptoms due to their Nav1.7
selectivity. Patients’ symptoms often worsen over time and many patients develop ulcerations and gangrenes
caused by excessive exposure to low temperature in order to relieve pain. This review mainly focuses on PE and
the causative gene SCN9A – its mutations and their effects on Nav1.7 channels’ electrophysiological properties. We
propose a genotype-channelopathy-phenotype correlation network underlying PE etiology which could provide
guidance for future therapeutics.
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Introduction
Pain, under physical conditions, informs body of harmful
stimuli, elicits protective reflexes, making it essential for
survival. Pathological pain, on the other hand, is one of
the most prevalent symptoms seen in patients. Chronic
pain has become a global health problem which is esti-
mated to affect about 30 % of adults worldwide [1].
Currently used drugs such as opioids and non-steroidal
anti-inflammatory drugs (NSAIDs) show limited efficacy
[2]. Thereby more precise medications for various types
of pain rising from different etiologies are required. As
one of the human heritable pain disorders, primary erythro-
melalgia (PE) is characterized by the triad of recurrent
burning pain, warmth and redness of the extremities. The
causative gene for PE, SCN9A, encodes a voltage-gated so-
dium channel (VGSC) subtype Nav1.7. Series of researches
on PE have elucidated a close relationship between aberrant
electrophysiology of VGSC (in this case Nav1.7) and hyper-
excitability of peripheral nociceptive neurons. PE plays a
pivotal role in understanding the molecular mechanisms
underlying pain caused by neuron hyperexcitability. This
review mainly focuses on PE and the causative gene SCN9A
– its mutations and their effects on Nav1.7 electrophysio-
logical properties. We also recapitulate utilization of
current treatments and updates of novel Nav1.7-targeted
agents, and propose an integrated perspective of a
genotype-channelopathy-phenotype network underlying
this intricate condition.* Correspondence: jianghong73868@126.com
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Definition
PE is a rare autosomal dominant neuropathy character-
ized by the triad of burning pain, recurrent redness, and
warmth of the extremities.
Nomenclature and classification
This rare and debilitating disorder was first reported and
named “erythromelalgia” according to its main symp-
toms (erythros-red, melos-limbs, algos-pain) by Mitchel
in 1878. Later the name “erythromelalgia” and “eryther-
malgia” were used respectively for cases secondary to
myeloproliferative disorders and idiopathic cases that
were refractory to aspirin. At present, erythromelalgia is
classified into PE and secondary erythromelalgia, based
on the absence or presence of diseases or drugs that
may associate with the onset or precipitation of its
symptoms [3, 4]. PE is exclusively caused by mutations
in SCN9A, the encoding gene of sodium channel subtype
Nav1.7 and can be sub-classified into familial (inherited
erythromelalgia) and sporadic forms. Secondary erythro-
melalgia is often associated with myeloproliferateive dis-
orders. In some cases, secondary erythromelalgia occurs
in paraneoplastic diseases and autoimmune neuropa-
thies. Though very rare, secondary erythromelalgia can
also appear in diabetes, rheumatologic diseases and in-
fectious diseases [5–9].
Epidemiology
PE is a rare neuropathy. Little is known in terms of the
global prevalence of PE. In a Norwegian clinical study of
87 patients with Erythromelalgia, the estimated annual
prevalence was 2/100,000 with primary cases making up
two-thirds of all cases [10]. A recent study in Sweden re-
ported that the incidence of erythromelalgia was 0.36/
100,000 though no incidence data regarding primary
form was shown [11]. In a population-based study in
Olmsted County, USA, the incidence was reported 1.3/
100,000. Male-to-female ratio of erythromelalgia differs
greatly in the aforementioned studies [12]. However,
these studies included both primary and secondary
forms of erythromelalgia, therefore providing limited in-
formation about prevalence/incidence of PE. Patients re-
ported present diverse nationalities (Chinese, American,
French, Dutch, Norwegian etc.) and geographical back-
grounds [13–36].
Clinical description
PE is characterized by the hallmark triad of recurrent
redness, burning pain, and warmth of the extremities in
virtue of exposure under heat, exercise and gravity and
can be relieved by cooling and elevation [37]. Clinical
onset of PE often takes place by the first decade but can
also display a broad range from congenital to early 60s
[19, 38]. Warmth, ambulation, physical exercise, sitting,
leg dependence and wearing shoes or gloves can provoke
and aggravate PE symptoms while immersion in ice/cold
water, uncovering affected areas, ventilation and eleva-
tion can ameliorate these symptoms [39]. In some cases
the symptoms precipitated during puberty, implicating a
hormonal role in PE pathophysiology [40].
Pain is the most disturbing symptom affecting PE pa-
tients and can be disabling. The pain is usually bilateral,
intermittent and severe, more often involving lower ex-
tremities than upper extremities [39]. Besides extrem-
ities, body parts such as hands and auricles being
affected have been reported [41]. Pain attacks usually
start with an itchy-like feeling and then progress to a se-
vere burning sensation as was reported by most patients,
with the durations of which ranging from several mi-
nutes to hours and even days. Pain symptoms are worse
in summer and at night and are usually provoked and
exacerbated by heat, ambulation, physical exercise, sit-
ting, leg dependence, and coverage of extremities [40].
Cooling and elevation are most effective ways to relieve
pain symptoms. According to patients, they would im-
merse affected limbs in ice water, uncover their feet dur-
ing sleep or walk barefoot in winter. Affected extremities
can develop ulceration and gangrene which are not dir-
ectly attributable to PE but are results of excessive ex-
posure to low temperature [42].
Apart from the common clinical descriptions, there
have been several reports about atypical PE cases with
comorbidities. Takahashi et al. described a PE patient
with wintry hypothermia and encephalopathy [43].




The causative gene for PE, SCN9A (GenBank:
DQ148960.1), was first identified and reported by
Yang et al. in 2004 [36]. SCN9A encodes Nav1.7, a
member of the VGSC family. Nav1.7 is preferentially
expressed in small-diameter nociceptive neurons and
can be up-regulated in the context of inflammation
[44]. It is now well characterized that Nav1.7 plays a
pivotal role of “threshold gate” in the generation of
action potentials for its ability to amplify small, slow
depolarizations and thus bringing the membrane po-
tential closer to the voltage threshold of action poten-
tial [45]. Due to the strong dependence of the action
potential on Nav1.7 in nociceptive neuron cells, mo-
lecular alterations in Nav1.7 caused by SCN9A muta-
tions can lead to nociceptive dysfunction. More than
70 mutations on SCN9A have been associated with
various clinical phenotypes, among which are pain
disorders including gain-of-function disorders PE and
paroxysmal extreme pain disorder (PEPD) as well as
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loss-of-pain disorder congenital insensitivity to pain
(CIP) [36, 46, 47]. To date, more than 20 mutations
have been reported responsible for PE [13–36].
Sodium channel and Nav1.7
Action potentials are triggered by noxious stimuli and
then propagated along the pain axis from peripheral to
central nervous system. During this process, VGSCs play a
pivotal role [48]. Nine subtypes of VGSCs, Nav1.1-Nav1.9,
have been identified in mammals, each holding distin-
guishable features and interacting with other VGSC mem-
bers in an intricate manner [49]. Analogous to other
VGSC subtypes, Nav1.7 is an integral membrane protein
that consists of a large alpha subunit and auxiliary beta
subunit(s) [50]. The alpha subunit forms the voltage-
sensitive and ion-selective pore, which predominantly de-
termines neural electrophysiological characters (Fig. 1).
The ion permeation pore is formed by proximal deploy of
the 4 domains within the alpha subunit [51]. More specif-
ically, the S1-S4 segments are considered voltage sensing
structures, where positive amino acids in S4 segments act
as gating charges that react to electrical field alteration
and confer conformation changes of the permeation pore,
thereby forming permeation pathways for Na + currents
[52]. Previous studies have demonstrated that the S4 seg-
ments in domain I and II determine voltage dependence
of activation, while those in domain III and IV contribute
to coupling activation and inactivation [53]. Particularly,
the DIIIS4/S5 linker sequence is highly conserved among
sodium channels, suggesting a conserved role in channel
function [23]. Close to the outer surface of the channel is
the narrowest part of the pore, where the linkers that con-
nect S5 and S6 segments form the locus of ion selectivity
[54], thereby mutations within this locus could lead to so-
dium channelopathies [18]. In addition, S6 segments in
domain III and III-IV linkers have been proofed crucial to
fast inactivation [35, 55]. These regions also contain drug-
binding spots involved in inactivation [51, 54, 56].
Nav1.7, the first sodium channel identified as a con-
tributor to chronic pain [57], produces rapid activation
and inactivation currents that are sensitive to sub-
micromolar levels of tetrodotoxin (TTX) [58]. Nav1.7 is
an important component in the peripheral nociceptors, as
has been proofed in series of studies on its gating proper-
ties, syndromes associated with its mutations and behav-
ioral tests in knock-out mice [45, 59]. Nav1.7 is also
characterized by slow closed-state inactivation through
which its own depolarizations (ramp currents) can be
Fig. 1 Schematic of voltage-gated sodium channel alpha subunit and localization of reported PE mutations. The alpha subunit consists of four
domains (I-IV). Each domain contains six helical transmembrane segments (S1-S6). The S4 segment of each domain contains positively charged
amino acid residues
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activated in response to small slow depolarizations close
to resting potentials [60–62]. Thus Nav1.7 channels have
the capacity of amplifying subtle depolarizations and play
the part of “threshold gate” in nociception pathways [45],
by virtue of escalating the membrane potential towards
the activation threshold of Nav1.8 channels, which gener-
ate all-or-none action potentials [63, 64]. The sophisti-
cated interaction between Nav1.7 and Nav1.8 may
elucidate divergent electrophysiology of dorsal root gan-
glia (DRG) and sympathetic neurons [45].
SCN9A mutations and neuron excitability
SCN9A, located on chromosome 2q31-32 [65], is a
highly polymorphic gene, with more than 70 mutations
residing within it associated with various clinical pheno-
types [17]. Yang et al. first narrowed down the candidate
gene of PE to VGSC genes, and identified 2 mutations
(L858H and I848T) residing in SCN9A. Since then more
than 20 PE mutations have been identified (Table 1). All
mutations alter the molecular constitution of Nav1.7
channels, resulting in clinical phenotypes with an ap-
proximate penetrance of 100 % [13–36]. About 3/4 of
the mutations have been localized to S4, S4/S5 linker, S5
or S6, suggesting pivotal physiological functions of these
structures and possible mutation hot spots [66].
So far, whole-cell voltage-clamp studies have shown
that PE mutations increase sensory neuron excitability
through hyper-polarized shifts in activation, depolarized
shifts in steady-state inactivation, slowed deactivations
and enhanced ramp currents [13–36]. Evidences showed
that these electrophysiological properties are altered in a
mutation-dependent manner.
Almost all PE-linked SCN9A mutant Nav1.7 channels
studied so far displayed hyper-polarized activations. Com-
puter simulations suggested that the hyper-polarized shifts
in activation were the major determinant for neuron
Table 1 SCN9A mutations and Nav1.7 electrophysiology





ΔV half (mV) ΔV half (mV) ΔV half (mV)
I136V D1S1 −5.7 −8 n.s. Increased Depolarized 9-22 [27, 29, 67]
Q10R D1S1 −5.3 −4.8 n.s. Unchanged Unchanged 14 [25]
Q10K D1S1 n.d. n.d. n.d. n.d. n.d. 0-20 [17]
I228M D1S4 n.s. +6.8 n.s. n.d. Depolarized 32-46 [20]
F216S DIS4 −11.8 −15.6 n.s. Increased n.d. n.d. [33, 102]
S211P DIS4 −8.2 −15 n.s. Increased n.d. 15 [22]
S241T DIS4/S5 linker −8.4 −12.3 n.s. Increased n.d. 2.5-10 [30, 34]
I234T DIS4/S5 linker −18 −21 n.s. Increased n.d. <1 [14, 103]
N395K DIS6 −7.7 +13 n.s. n.d. n.d. <10 [28]
V400M DIS6 −6.5 n.s. +7.3 Increased n.d. <1 [104, 105]
G616R DIDII loop n.s. n.d. +5.7 Increased n.d. 24 [81]
L823R DIIS4 −14.6 n.d. −9.8 n.d. n.d. <1 [24]
I848T DIIS4/S5 linker −13.8 Hypopolarized n.s. Increased Depolarized 4-8 [36, 67, 76]
L858H DIIS4/S5 linker −13.3 Hyperpolarized n.s. Increased n.d. 4-8 [36]`[76, 106]
L858F DIIS4/S5 linker −9 n.s. +3.1 Increased n.d. 0-2 [38]
A863P DIIS5 −8 n.s. +10 Increased Depolarized Preschool [31]
V872G DIIS5 −9.3 n.d. n.s. Increased n.d. 5 [89]
Q875E DIIS5 −17.5 −22.8 n.s. n.d. n.d. 2 [13, 40]
Del-L955 DIIS6 −24 −39 n.s. Increased n.s. 15 [16, 21]
F1449V DIIIDIV −7.6 Hyperpolarized +4.3 Unchanged Unchanged 3 [35]
P1308L DIIIS4/S5 linker −9.6 n.s. +16.1 Increased n.s. 2 [23]
V1316A DIIIS5 −9.3 −10 n.s. Increased n.d. 9 [18]
A1632E DIVS4/S5 linker −7 +3.5 +17 Increased Depolarized n.d. [26]
W1538R DIVS2 −8.6 n.s. n.s. n.d. n.d. 3 [19]
A1632T DIVS5 n.s. n.s. +8 Unchanged Unchanged 17 [15]
A1746G DIVS6 −15.6 −32 n.s. n.d. n.d. 61 [19]
n.d not determined. n.s not significant
Tang et al. Orphanet Journal of Rare Diseases  (2015) 10:127 Page 4 of 11
hyperexcitability induced by PE mutations [26, 28]. To its
contradictory, a recent study on a well-identified mutation
I848T under 35 °C found that the hyperpolarizing shift in
activation diminished under this temperature whereas the
depolarizing shift of inactivation remained [67]. This find-
ing suggests a need for reassessment of the close relation-
ship between activation shifts and clinical symptoms [15].
The mechanisms through which hyperpolarized shifts in
activation contribute to the hyperexcitability of sensory
neurons are that the leftward shifts, with or without a
change in steady-state inactivation, increase the overlap
between activation and inactivation curves. Researches
have demonstrated that this increased overlap enhances
ramp currents in Nav1.7 mutant cells compared to wild-
type cells, leading to depolarized resting membrane poten-
tials (RMP) [68–70]. The depolarized RMP, as a result,
moves closer towards the voltage threshold of Nav1.8
(−16 to −21 mV) [71], which is responsible for the major
currents during the upstroke of the all-or-none action po-
tentials in sensory neurons [63, 64].
Del-L955 is an in-frame deletion mutation in SCN9A
that produces large negative shifts in both activation and
slow inactivation. When compared with L858F, a muta-
tion which only causes similar extent of negative shifts
in activation but not in slow inactivation, Del-L955
showed attenuating effect on the hyperexcitability in
sensory neurons. The result indicates that while the in-
creased overlap between activation and slow inactivation
renders sensory neurons hyperexcitable, negative shifts
in slow inactivation could alter electrophysiological
properties of neuron cells in a hypoexcitable direction.
Several mechanisms underlie enhanced ramp currents
in mutant Nav1.7 channels. First, the rightward shifts of
steady-state inactivation, accompanied by leftward shifts
of activation, amplify ramp currents. Consistently, F1449V
mutant channel, which depolarizes steady-state inactiva-
tion, displays similar ramp currents with wild-type chan-
nels [21]. Studies of other mutations in SCN9A (S241T,
V400M, A863P, etc.) all showed aforementioned alter-
ations in channel properties and increased ramp currents.
Second, the onsets of inactivation are slower in mutant
channels compared with wild-type channels. Slow closed-
state inactivation of the wild-type Nav1.7 has been associ-
ated to the production of large ramp currents [61], so a
decrease in the rate of onset of closed-state inactivation
would possibly enhance subthreshold currents [32]. Third,
under physiological condition, deactivation rate (e.g. so-
dium channels undergo an open-to-close state) is much
larger than inactivation rate at negative potential less than
-45 mV [72]. The ability of sodium channels to open and
reopen depends more on deactivation rather than inacti-
vation process [72]. However in some mutant channels,
take L858F for example, at voltage potentials around
-70 mV, deactivation rate is much slower than that of
wild-type channels. This permits more channel to open
and therefore increasing ramp currents [61]. Indeed,
L858H, which possesses slower deactivation kinetics than
L858F, creates larger ramp currents [32]. The L858 locus
seems to play a major role in modulating both deactiva-
tion kinetics and production of subthreshold currents.
The enhanced ramp currents lead to higher availability
of sodium channels at RMP during activation and fast
inactivation [73]. In DRG neurons, because the ramp
currents are triggered in the vicinity of resting potentials
(−70 to -40 mV) [74, 75], the larger ramp currents in
neurons expressing mutant Nav1.7 channels can amplify
small depolarizing inputs, which in turn increases the
excitability of DRG neurons [76]. Given the fact that
Nav1.7 channels are expressed in small, mostly nocicep-
tive sensory neurons, the alterations in activation, slow
inactivation, deactivation and ramp currents provide ex-
planations to the amplified pain symptoms observed in
PE patients [77].
Mutant-specific effects on Nav1.7 electrophysiology
Besides general channelopathies in PE mutant Nav1.7
channels, studies that focused on particular mutations
have shed light upon mutant-dependent mechanisms
underlying Nav1.7 channelopathies [24, 30, 33, 36]. For
instance, several studies have reported that altered
charge of Nav1.7 residues can produce functional abnor-
malities in these channels. Consistently, L858H and
L823R introduce an additional positive charge into S4
segment on DII of Nav1.7 channel. Pronounced hyper-
polarizations in activation have been observed in both
L858H and L823R transfected cells (−13.3 mV and
−14.6 mV respectively), raising the possibility that
charge alterations may underlie the large negative shifts
of activation in these mutations [24]. However, another
mutation F216S that substitutes a charged residue with
an uncharged one, was also studied and found to pro-
duce a shift in activation of −11.8 mV [33]. Therefore
addition or reduction of charge may not be a major
modulator of Nav1.7 physiology.
The size of amino acid residues of certain loci might
also influence Nav1.7 channel functions. Mutation S241T
substitutes serine with threonine, both of which have simi-
lar biochemical properties and are polar amino acids, ex-
cept for that threonine possesses a larger side chain
relative to serine, suggesting that the physiological alter-
ation in mutant Nav1.7 channels may be affected by the
size of the mutant amino acid residues [30].
Nav1.8’s effect on neuron excitability
Researchers have observed an interesting dual manifest-
ation of PE, the divergent functional effects of SCN9A
mutations on sensory neurons and sympathetic
neurons. Mutant Nav1.7 channels render DRG neurons
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hyperexcitable but increase action potential threshold in
sympathetic neurons [78]. Disparate to Nav1.7, Nav1.8
channels have a more depolarized voltage dependence of
activation (−16 to -21 mV) and primarily underlie the ac-
tion potential upstrokes [64]. Studies have shown that
Nav1.7 channels are expressed at a high level in both sen-
sory neurons and sympathetic neurons [79], while Nav1.8
channels are mostly expressed in sensory neurons [68].
Additionally, when co-expressed with L858H mutant
channel in supra cervical ganglion (SCG) neurons, Nav1.8
tend to protect against the hyperexcitability caused by
Nav1.7 mutant channels [68]. Thus, different cell back-
grounds, in this case the expression levels of Nav1.8,
might have impacts that correlate with direct effects of
Nav1.7 mutations on neuron cells.
Genotype-phenotype correlation
PE harbors complex genotype-phenotype correlations.
Multiple studies have demonstrated that different clin-
ical genotypes have varied influences on phenotypes,
and that one genotype can produce distinct clinical phe-
notypes among different individuals.
Clinical symptoms of PE seem to be mutation-
dependent. Generally, most PE patients experienced onset
of disease by the first decade of life. However, patients in a
Taiwan family encountered the onset of PE symptoms at
an average age of 9–22 years old, with the progression to
involve hands taking longer time than that seen in most of
other PE pedigrees [27]. The causative mutation, I136V, is
located within S1 segment in the first domain, which has
not been proofed to have a dominant contribution in
channel gating [27]. It causes a relatively minor shift in ac-
tivation (−5.7 mV), suggesting that smaller effects on
Nav1.7 channels of certain mutations may be associated
with a late onset [27]. Another mutation Q10R, also lo-
cated in S1 segment in the first domain, was reported to
produce an even milder shift in activation [25]. Thereby it
appears that the loci of mutation could have certain effects
on the phenotype through modulating Nav1.7 gating
properties. Interestingly, another mutation Q875E, which
shifts voltage dependence of activation by −17.5 mV, was
identified in a patient whose symptoms occurred at the
age of 15 [13]. Thus the relationship between the effects
of mutations and clinical phenotypes should not be strictly
causal and other underlying factors should be considered
and studied.
Multiple studies have suggested that large shifts in acti-
vation are related to early onsets of PE and small shifts in
activation are related to late onsets of PE. A study on an
in-frame deletion mutation Del-L955 found that this mu-
tation produced the largest shift in slow inactivation
(−39 mV) studied to date [21]. This strong enhancement
of slow inactivation could reduce channel availability, thus
attenuating neuron excitability induced by hyperpolarized
activation [21]. In consistent, another mutation A863P,
also located in the second domain, depolarizes slow inacti-
vation by 10 mV. A patient with A863P was reported to
experience disease onset at preschool period [31].
A1632E mutation presents electrophysiological charac-
teristics of both PE (hyperpolarized activation, slowed
deactivation and increased ramp currents) and PEPD
(impaired fast inactivation) [26]. A1632E resides in the
linker between S4 and S5 segments in the fourth do-
main, which is highly conservative in sodium channels,
suggesting an important role of the S4/S5 linker in chan-
nel’s electrophysiological functions. In addition, the
A1632E is close to M1627K, one of the PEPD mutations;
thereby the mutations on physiological continuum can
lead to phenotypes combining distinct pain disorders.
Another similar mutation A1632T, which introduces less
negative charges to a same locus, leads to PE phenotype
without PEPD phenotype [15]. Researches have demon-
strated that the negative charge introduced by A1632T
has an effect of stabilizing fast inactivation thus attenu-
ating the PEPD phenotype [15]. Additionally, I228M was
reported to produce distinct clinical phenotypes in 3 dif-
ferent patients (one PE, the other two small fiber neur-
opathy) with ages of onset ranging from 32–46 years
[20]. Whether the phenotypic diversity is attributable to
modifier genes or environment factors still needs fur-
ther study and will provide deeper insight into patho-
genesis of PE.
Previous studies has reported that 4 splice variants
of Nav1.7 exist in DRG neurons, including neonatal
(N)/adult (A) from exon5 and short (S)/long (L) from
exon11 [80]. An increase in expression level of
Nav1.7AL has been observed in mature rat DRG neu-
rons [81]. As was reported, G616RAL mutation af-
fects Nav1.7 channel gating properties by enhancing
excitability, in ways of depolarizing steady-state inacti-
vation. This electrophysiological change is not seen in
G616RNS mutant Nav1.7 [81]. However the hyperex-
citability distinguishes from other PE mutations in
ways that G616R only depolarizes inactivation while
most of other PE mutations hyperpolarize activation.
Notably, another study on splice variants of Q10R did
not find difference of neuron excitability between
adult and neonatal splice isoforms [25]. So even if
splice variant can explain the variable ages of onset,
the validity of using splice variant to explain other
PE-linked neuron hyperexcitability requires further
investigations.
On systemic level, Nav1.7 channels are also expressed
in central nervous system involved in pain perception and
emotional integration, including hypothalamus, habenula
and amygdala, suggesting contributions of mutant Nav1.7
channels to higher order misinterpretation of pain [14].
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Moreover, alterations of electrophysiology in a certain
voltage gated ion channel, as reported, can induce com-
pensatory functional alterations in other ion channels
[82]. So the broad range of onset age and phenotypic
variation could be possibly illuminated by distinguished
compensatory mechanisms among individuals.
Diagnosis
The diagnosis of PE depends on clinical history and
physical examinations. Triad of recurrent redness, burn-
ing pain, and warmth of the extremities is the diagnostic
hallmark of erythromelalgia. A detailed review of pa-
tients’ medical history is necessary to provide informa-
tion about possible factors that might lead to secondary
erythromelalgia. A positive or negative family history
can further help to confirm familial/sporadic subclassifi-
cation of PE. Auxiliary tests such as complete blood
count, imaging studies and thermograph can be given
for exclusion of other differential diagnoses and second-
ary erythromelalgia. Histological analysis is not regarded
as a routine diagnostic method in PE and is usually per-
formed in severe cases because of limited specificity
[83]. Reported histological changes in skin biopsy in-
cluded perivascular lymphocytic inflammation, perivas-
cular edema (arteriolar endothelial cell swelling and
enlarged nuclear) and arteriolar smooth-muscle hyper-
plasia [84]. In some cases, a significant reduction in the
number of small fibers might be found [29]. Also, there
have been reports about axonal neuropathy in nerve bi-
opsy and neurogenic atrophy in muscle biopsy [14].
Since biologic markers for PE are not established, a full
diagnosis of PE should be carefully made upon the com-
bination of clinical exam findings and detection of a mu-
tation on SCN9A. In the absence of general guidelines
for SCN9A mutation testing, genetic tests can be consid-
ered in young patients with positive family history and
with secondary etiologies excluded [40].
Differential diagnosis
To differentiate PE from secondary erythromelalgia, clin-
ical conditions (myeloproliferative disorders, neoplasms,
rheumatologic diseases), medications (bromocriptine,
calcium channel blockers such as nifedipine, felodipine,
and nicardipine and topical isopropanol), substances
(mushroom/mercury poisoning) or poxvirus (Chinese epi-
demic of erythromelalgia) should be carefully reviewed
[85]. Due to some shared clinical similarities (severe pain
and vasomotor disturbances), PE needs to be differenti-
ated from Fabry disease, which is a rare genetic disorder
that causes lipid metabolism aberration and is character-
ized by burning pain and acroparesthesias in the extrem-
ities. A decreased plasmatic level of α –galactosidase A is
crucial in the diagnosis of Fabry disease [86]. Other differ-
ential diagnoses include Raynaud phenomenon, frostbite,
vasculitis, cellulitis, erysipelas, dermatitis, osteomyelitis,
complex regional pain syndrome, systemic lupus erythe-
matosus (SLE), peripheral neuropathy, arterial or venous
insufficiency and gout [40].
Genetic counseling
Up to now, there are no general guidelines for genetic
test on PE mutations. Upon exclusion of secondary eti-
ology, patients with a positive family history can con-
sider genetic test. Genetic test is influential to family
planning because probability of an offspring to inherit
the same condition is 50 % [40].
Treatment
Most cases of PE are refractory to pharmacotherapy and
the response to pain therapeutics shows a great hetero-
geneity [42]. Recent studies have shown that therapeutic
inefficiency can be explained by SCN9A-linked conform-
ational alterations of the binding locus of local anesthetic
agents [18, 28]. For this reason, sodium channel blockers
that depend on this mechanism usually display limited ef-
ficacy. One study estimated that lidocaine only relieves
pain symptom in 55 % PE patients [28]. Therapeutic win-
dow of lidocaine is also hindered because of potential sig-
nificant cognitive, motor and cardiac side effects [45]. In
some cases, lidociane produced efficacious pain relief, but
long term usefulness was limited [87]. A study compared
the effect of lidocaine on N395K versus F216S and dem-
onstrated that mutations located in local anesthetic bind-
ing site may be an important determinant for the
unsatisfactory drug efficacy [28]. Mexiletine, an anti-
arrhythmic agent analogous to lidocaine, was reported to
greatly improve pain symptoms in some young PE
patients [88]. Additionally, a patient carrying V872G
mutation showed favorable response to mexiletine with
long-lasting improvement of symptoms [89]. Later it was
demonstrated that V872G increased use-dependent effect
of mexiletine in PE patients, which could be a therapeutic
mechanism more important than tonic block effect. An
anti-epilepsy drug, carbamazepine (CBZ) which decreases
voltage dependence of fast inactivation of sodium chan-
nels to more hyperpolarized potentials [90–92] also pro-
vided sensitive pain relief in a three-generation family
carrying V400M mutation and a two-generation family
carrying I848T [35, 93].
In congenital insensitivity to pain (CIP), a loss-of-
function inherited neuropathy, patients do not express
Nav1.7 channels. But their insensitivity to pain is not
related to deficits in cognitive, sensory or motor abil-
ity [94]. A complete Nav1.7 knock-out animal model
by null mutations did not show dysfunction of other
sodium channel within DRG neurons. This indicates
that Nav1.7 could be an ideal target for novel pain-
relieving drugs [45].
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Several novel Nav1.7-selectvie agents are undergoing
clinical trials and display desirable efficacy. An oral
administrated Nav1.7 channel modulator, PF-05089771,
has completed phase II clinical trial of PE [95]. Another
Nav1.7 channel blocker, TV-45070 (formerly XEN402),
which is administrated through topical approach, has
been granted orphan drug for PE [96] and is now under-
going phase II proof-of-concept clinical trial of PE [97].
In addition, the tarantula venom peptides ProTx-I and
ProTx-II stand out from other sodium channel blockers
in that ProTx-I and ProTx-II shift activation of VGSCs
positively while most of other sodium channel blockers
modulate inactivation process [98]. Notably, it is re-
ported that ProTx-II selectively inhibited to Nav1.7 and
completely prevented activation of evoked C-fiber at
concentrations that had little effect on Aβ-fiber conduc-
tion [99]. Besides nonspecific or Nav1.7-selectvie sodium
channel blockers, an experiment using anti-Nav1.7 se-
quences via viral delivery was reported to attenuate in-
flammatory pain in animal models [100], thus providing
more possibilities concerning therapeutic approaches.
In addition, other reported topical therapies for PE
involve midodrine and botulinum toxin. Thoracic
sympathectomy has been reported to have successful
clinical outcomes [101]. Besides, non-pharmaceutical
treatments include cooling or elevating the affect ex-
tremities, avoiding excessive warming and long-time
standing or exercise.
Prognosis
Most PE patients remain refractory to sodium chan-
nel blockers and their symptoms progress overtime.
Most patients will develop self-mutilating behaviors
or tissue damage such as ulceration, necrosis, and
gangrene of affected extremities. Patients’ quality of
life is greatly compromised and disability is not rare
due to intolerable pain, secondary tissue damage or
self-mutilating behaviors.
Conclusion
Since the identification of SCN9A, more than 20 PE mu-
tations have been reported. Researches into PE have
shed light upon the pivotal role of voltage-gated sodium
channels in sensory neurons’ physical properties and
have elucidated the underlying pathogenic mechanisms
caused by SCN9A-linked Nav1.7 mutations. Electro-
physiology studies of mutant Nav1.7 channels have
presented us a complex yet intriguing network of
genotype-channelopathy-phenotype correlation, through
looking into which more aspects of the nociception
pathways can be clarified. Studies on CIP caused by loss-
of-function mutations in Nav1.7 and Nav1.7 knock-out
mice models suggest that Nav1.7 is an ideal target for
novel pain-relieving drugs. Furthermore, several novel
Nav1.7-selectvie agents have showed satisfactory clinical
efficacy. In order to delineate an overall picture of this
rare and intricate pain disorder, several questions remain
to be answered such as whether molecular modulators
or non-coding regions of SCN9A also contribute to the
mechanisms of PE? What explains for the disproportion-
ate relationship between the level of channelopathies
and phenotypes? Whether Nav1.7-specific blockers have
therapeutic value in all gain-of-function SCN9A muta-
tions? What remains elusive may be the keystone to
bridge the gap between basic researches to clinical treat-
ments for PE.
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